Unknown

Dataset Information

0

Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.


ABSTRACT: Asparaginase, an agent used in the treatment of acute lymphoblastic leukemia (ALL), is associated with the development of pancreatitis. The clinical course and long-term outcome of patients experiencing this complication has not been extensively detailed.We reviewed the clinical course for all children with ALL diagnosed with pancreatitis at the Dana-Farber Cancer Institute/Children's Hospital Boston between 1987 and 2003. The outcome of these patients was compared with that of patients with ALL who did not experience pancreatitis.Twenty-eight of 403 children (7%) were diagnosed with pancreatitis. Patients 10-18 years old at diagnosis had 2.4 times the risk of developing pancreatitis compared with younger patients. Pancreatitis typically occurred early in the course of therapy (median 4 weeks after first dose of asparaginase). Ninety-three percent of affected patients were hospitalized and 57% received parenteral nutrition. No patient developed chronic sequelae or died as a result of pancreatitis. Sixteen (57%) patients were re-treated with asparaginase, 10 of whom had another episode of pancreatitis. No significant differences in event-free survival were observed when comparing patients with and without a history of pancreatitis.Asparaginase-associated pancreatitis was more common in older children, and caused significant acute morbidity. It tended to occur after the first few doses of asparaginase, suggesting a predisposition to this complication rather than a cumulative drug effect. Re-treatment with asparaginase after an episode of pancreatitis was associated with a high risk of recurrent pancreatitis.

SUBMITTER: Kearney SL 

PROVIDER: S-EPMC2721691 | biostudies-literature | 2009 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.

Kearney Susan L SL   Dahlberg Suzanne E SE   Levy Donna E DE   Voss Stephan D SD   Sallan Stephen E SE   Silverman Lewis B LB  

Pediatric blood & cancer 20090801 2


<h4>Background</h4>Asparaginase, an agent used in the treatment of acute lymphoblastic leukemia (ALL), is associated with the development of pancreatitis. The clinical course and long-term outcome of patients experiencing this complication has not been extensively detailed.<h4>Procedure</h4>We reviewed the clinical course for all children with ALL diagnosed with pancreatitis at the Dana-Farber Cancer Institute/Children's Hospital Boston between 1987 and 2003. The outcome of these patients was co  ...[more]

Similar Datasets

| S-EPMC4819847 | biostudies-literature
| S-EPMC8946594 | biostudies-literature
| S-EPMC9745725 | biostudies-literature
| S-EPMC4258187 | biostudies-literature
| S-EPMC3516853 | biostudies-literature
| S-EPMC8992626 | biostudies-literature
| S-EPMC6953441 | biostudies-literature
| S-EPMC9279693 | biostudies-literature
2006-01-21 | GSE4070 | GEO
2006-01-20 | E-GEOD-4070 | biostudies-arrayexpress